Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1995 2
1996 2
1998 2
1999 2
2000 4
2001 5
2002 4
2003 7
2004 7
2005 13
2006 12
2007 15
2008 15
2009 8
2010 10
2011 12
2012 15
2013 16
2014 27
2015 31
2016 12
2017 4
2018 14
2019 13
2020 17
2021 21
2022 15
2023 16
2024 14
2025 17
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Results by year

Filters applied: . Clear all
Page 1
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Hummel HD, et al. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. Immunotherapy. 2021. PMID: 33172323 Free article. Clinical Trial.
Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE( )) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. ...
Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE( )) immune therapy mediatin …
Kappa/Lambda light-chain typing in Alzheimer's Disease.
Kaya ZZ, Tuzuner MB, Sahin B, Akgun E, Aksungar F, Koca S, Serdar M, Sahin S, Cinar N, Karsidag S, Hanagasi HA, Kilercik M, Serteser M, K Baykal AT. Kaya ZZ, et al. Curr Alzheimer Res. 2022;19(1):84-93. doi: 10.2174/1567205019666220131101334. Curr Alzheimer Res. 2022. PMID: 35100957
Central precocious puberty in boys; diagnosis, treatment and follow-up: a nation-wide study.
Odabasi Gunes S, Sakar M, Muratoglu Sahin N, Karaguzel G, Cimbek EA, Darendeliler F, Sarban E, Doger E, Oner G, Siklar Z, Senyazar G, Aydin M, Ozkan B, Sangun O, Parlak M, Akin O, Sahin KC, Esen İ, Kilinc Ugurlu A, Seymen G, Bolu S, Sobu E, Ozalkak S, Demet Akbas E, Buyukyilmaz G, Selver Eklioglu B, Ucar A, Kocaay P, Tunc S, Bas S, Dundar İ, Celebi Bitkin E, Torel Ergur A, Bingol Aydin D, Kirel B, Ata A, Atar M, Isakoca M, Aytac Kaplan EH, Kontbay T, Tepe D, Ercan O, Boyraz M, Akyurek N, Unal E, Ozcan Murat N, Koca SB, Kocabey Sutcu Z, Oznur Muz FN, Cetinkaya S. Odabasi Gunes S, et al. Endocrine. 2025 Nov;90(2):831-843. doi: 10.1007/s12020-025-04382-w. Epub 2025 Aug 11. Endocrine. 2025. PMID: 40790098

Basal luteinizing hormone (LH) and total testosterone (T) levels were higher in oCPP group than in iCPP group (p = 0.004 and p = 0.02, respectively). Basal LH, basal follicle-stimulating hormone (FSH), T, and peak LH/FSH were lower in the iCPP-obese group (p < 0.

…
Basal luteinizing hormone (LH) and total testosterone (T) levels were higher in oCPP group than in iCPP group (p = 0.004 and p = 0.02 …
Structures and mechanisms of glycosyltransferases.
Breton C, Snajdrová L, Jeanneau C, Koca J, Imberty A. Breton C, et al. Glycobiology. 2006 Feb;16(2):29R-37R. doi: 10.1093/glycob/cwj016. Epub 2005 Jul 21. Glycobiology. 2006. PMID: 16037492 Review.
Can Botulinum-A Toxin Be Used to Delay Ejaculation: Results of an Ejaculation Model in Male Rats.
Ongün Ş, Acar S, Koca P, Uzut M, Esen AA, Durmus N, Demir O. Ongün Ş, et al. J Sex Med. 2019 Sep;16(9):1338-1343. doi: 10.1016/j.jsxm.2019.06.002. Epub 2019 Jul 2. J Sex Med. 2019. PMID: 31277970
CONCLUSIONS: Injection of botulinum-A toxin into the BS muscle in rats significantly delayed the ejaculation latency time and affected the expulsion phase. Ongun S, Acar S, Koca P, et al. Can Botulinum-A Toxin Be Used to Delay Ejaculation: Results of an Ejaculation Model i …
CONCLUSIONS: Injection of botulinum-A toxin into the BS muscle in rats significantly delayed the ejaculation latency time and affected the e …
Versatile functions of methyl-CpG-binding domain 2 (MBD2) in cellular characteristics and differentiation.
Lekesiz RT, Koca KK, Kugu G, Çalışkaner ZO. Lekesiz RT, et al. Mol Biol Rep. 2025 Mar 15;52(1):316. doi: 10.1007/s11033-025-10411-8. Mol Biol Rep. 2025. PMID: 40089655 Review.
This review focuses on the cell-specific functions of MBD2 isoforms (MBD2a, MBD2b, and MBD2c(t)) in cellular differentiation, reprogramming, and the immune system. Furthermore, the relevance between MBD2 and certain cancers was discussed for the first time in this paper. . …
This review focuses on the cell-specific functions of MBD2 isoforms (MBD2a, MBD2b, and MBD2c(t)) in cellular differentiation, reprogr …
A brief summary of clinical types of psoriasis.
Sarac G, Koca TT, Baglan T. Sarac G, et al. North Clin Istanb. 2016 Jun 14;3(1):79-82. doi: 10.14744/nci.2016.16023. eCollection 2016. North Clin Istanb. 2016. PMID: 28058392 Free PMC article. Review.
Psoriasis is a chronic inflammatory dermatosis that is thought to onset as a result of T lymphocyte-mediated immunological response. Disease may manifest itself in different modalities with regard to clinical features and severity. ...
Psoriasis is a chronic inflammatory dermatosis that is thought to onset as a result of T lymphocyte-mediated immunological response. …
Genotype, Phenotype Characteristics and Long-Term Follow-Up of Patients with Vitamin D-Dependent Rickets Type IA: A Nationwide Multi-Centre Retrospective Cross-Sectional Study.
Cayir A, Demirbilek H, Türkyılmaz A, Turan S, Bereket A, Darendeliler F, Özbek MN, Koca SB, Unal E, Okdemir D, Esen I, Eren E, Yıldırım R, Cetinkaya S, Sahin KC, Anık A, Dönmez AS, Öztürk AP, Bayramoglu E, Buyukinan M, Gurbuz F, Demir K, Kılınç S, Buyukyilmaz G, Kaygusuz SB, Çelmeli G, Eklioglu BS, Acar S, Dursun F, Turan I, Özkaya B, Kurnaz E, Baran RT, Özkan B. Cayir A, et al. Horm Res Paediatr. 2025 Jul 2:1-9. doi: 10.1159/000546497. Online ahead of print. Horm Res Paediatr. 2025. PMID: 40602383
The most common mutation was a splice-donor-site mutation (c.195+2T>G) (n = 42), followed by a 7-bp duplication 1319-1325dupCCCACCC (Phe443Profs*24) (n = 25), and two missense mutations p.K192E (c.574A>G) (n = 17) and c.1474C>T (p.R492W) (n = 12). The novel c.195+ …
The most common mutation was a splice-donor-site mutation (c.195+2T>G) (n = 42), followed by a 7-bp duplication 1319-1325dupCCCACCC (Phe4 …
310 results